02552.HK
Hua Medicine (Shanghai) Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.18
−3.76%Year over year
Reported trailing growth
- Revenue
- +73.9%
- EBITDA
- +60.9%
- EBIT
- +54.8%
- EPS
- —
- Free cash flow
- +86.5%
- Operating cash flow
- +88.4%
Forward estimates
Based on analyst estimates
- Revenue
- +304.4%
- EBITDA
- +3078.5%
- EPS
- +1737.0%
Three-year CAGR
- Revenue
- +201.0%
- EBITDA
- +66.6%
- EBIT
- +60.0%
- Net income
- +530.8%
- EPS
- +536.0%
- Free cash flow
- +85.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026